Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 2nd International Conference on Hepatology Chicago, Illinois, USA.

Day 1 :

Keynote Forum

David H Van Thiel

Advanced Liver and Gastrointestinal Disease Centre, USA

Keynote: Endocan a valuable biomarker for hepatocellular carcinoma (HCC)

Time : TBD

OMICS International Hepatology 2016 International Conference Keynote Speaker David H Van Thiel photo

David H Van Thiel obtained his MD from the University of California at Los Angeles and completed Internal Medicine residencies at Cornell University Hospitals and Boston University. He completed a Gastrointestinal/Hepatology fellowship at Boston University and the University of Pittsburgh. At the latter institution, he progressed from an Instructor of Medicine to Professor of Medicine and Director of the Gastroenterology Hepatology Program and served as the medical Director of Liver transplantation. He has published more than 100 peer reviewed papers in a variety of journals and is on the Editorial Board of several journals as well as serves as a Reviewer.


Hepatocellular carcinoma (HCC) occurs at the rate of more than 500,000 cases and is the 6th most common cause of cancer worldwide. It is also the 3rd leading cause of cancer related death. Currently, increasing number of cases of hepatocellular carcinoma are being referred for liver transplantation as a result of changes in the MELD score points awarded to such individuals. A host of laboratory and imaging studies are utilized currently to detect in the resected hepatic tissue, tumor size within the resected specimen, and the presence of satellite nodules as well as the presence of additional foci of tumor and an alpha-fetoprotein level greater than 750 post intervention have been utilized to address this latter issue. The major problem with these analysis is that they can only be addressed after the intervention has ocurred. What is needed is a biomarker that can be utilized prior to either a non surgical or surgical intervention that identifies cases with a high likelihood of cure or alternatively a high likelihood of having a long-term survival that justifies the intervention. Endocan is a soluble proteoglycans of 50 kD that is over expressed by endothelial cells in several different carcinomas and is associated with a change in endothelial status from that of a dormant cell to one associated with fast-growing tumor and enhanced tumor progression. As such, endocan may be the useful marker for guiding clinicians at selecting the best therapy (radiofrequecy ablation, radioactive beads, chemoembolization, resection or transplantation) for individuals with HCC. Moreover, it would appear to be an important target for future immunotherapeutic approaches for the treatment of hepatocellular carcinoma by inhibiting endocan activity, thereby inhibiting tumor growth and progression (metastases).

OMICS International Hepatology 2016 International Conference Keynote Speaker Trent W Nichols photo

Trent W. Nichols Jr. MD, is an internist, nutritionist, and gastroenterologist with more than 30 years of clinical experience. He is the founder and director of the CNDD and the Advanced Magnetic Research Institute in Hanover, Pennsylvania. He is a graduate of the University of Denver with a BS in Chemistry and Northwestern University with a MD. His postgraduate education medicine was at Northwestern University in Internal Medicine and Fellowship in Gastroenterology and Hepatology. He has been the lead investigator in over 50 pharmaceutical trials and has worked for the Veterans Administration, Kaiser Permanente, Good Samaritan Hospital in Lebanon PA, and Sinai Hospital In Baltimore MD. He is a member of the American Gastroenterology Association, Society for Neuroscience, and Bioelectromagnetic Society. He is on the editorial panel of the Journal of Liver OMICS and has been active researcher in the role of mitochondrial dysfunction in liver disease and therapy with EMF.


Liver cancer (HCC) is increasing in the USA and around the world. Although there is now effective therapy for Hepatitis C, fatty liver (NAFLD/NASH) has no recognized medical therapy other than weight loss. However, Metformin and PPAR gamma agonist have been associated with lower risk and improved prognosis of HCC. More than 95 % of patients with HCC have either upregulation in the signaling protein Wnt or its receptor Frizzled, or down–regulation of Frizzled receptors making the WntT/β-Catenin pathway a potential important therapeutic target according to an article in the Journal for Cancer Research. Current strategies for disrupting Wnt signaling include monoclonal antibodies against Wnt protein or the Frizzled receptor using soluble receptors for Frizzled to neutralize Wnt. Another approach is by using GPC3 a heparin sulfate proteoglycans that act as Wnt co-receptors of modulators. We will discuss the WNT/βCatenin pathway and then review the many genes (polygenetics) in obesity and fatty liver (NAFLD/ NASH) and the epigenetics of methylation involved in NASH and HCC. Additionally the mitochondrial defects seen in the metabolic syndrome will be discussed. Until recently, this hypothesis that has received little attention and that is the mitochondrial defects seen in metabolic syndromes or diabetes 2, fatty liver and insulin resistance. In our past experiments, moderate magnetic fields of 0.5T change 2, 500 gene expressions with dramatic changes in mouse morphology, liver fat and metabolism!. Genes involved in Wnt signaling were down regulated in NASH but have been up-regulated in HCC. Research of the author in mice and humans will be reviewed and gene array analysis of human embryonic stem cells in another experiment of 0.23-0.28 T static magnetic fields by Wang and Yarema collaborators at JHU will be discussed. Up-regulation of genes for insulin factors genes, peroxisome proliferative activity receptor were increased, and calcium channel gene and other genes for mitochondrial ribosomal protein S, and uncoupling protein 2. Down- regulation of tumor necrosis factor alpha and up- regulation of TLR 4 via Wnt signaling and interleukin 6 were demonstrated for this transformation. A methylated gene in obesity has recently been published by Su which is also affected. Mitochondrial dysfunction in obesity, fatty liver and NASH has previously been described. Forkhead transcription factors are also up-regulated at 5 days. Of the 47 genes up regulated in NASH by a study by Bertola. 13 were identified as down-regulated by SMF and 2 up-regulated. Genes for fibrosis are also down-regulated. The use of high dose vitamin D3 in prevention will be discussed starting with the European Prospective Investigation into Cancer and Nutrition publication and then the Vitamin D signaling pathways as potential for anticancer therapeutics with their potential as anticancer agents because their administration has antiproliferative effects, activation of apoptotic pathways and inhibition angiogenesis.